SCHEMBL5791933

SCHEMBL5791933

Cc1ccc(-c2nccn2-c2ccc(F)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
TSHR P16473 1/20 0.44
ABCB1 P08183 1/20 0.43
ACHE P22303 1/20 0.43
LMNA P02545 2/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PLK2 Q9NYY3 2/20 0.42
PLK1 P53350 1/20 0.42
KDR P35968 3/20 0.42
SRC P12931 1/20 0.42
BRAF P15056 1/20 0.42
MAPK1 P28482 2/20 0.41
MITF O75030 1/20 0.41
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1052342 1.00 EGFR (0.45) EGFRMEN1KMT2ATSHRABCB1
SCHEMBL28026878 0.85 KDR (0.48) EGFRMAPK9MAPK10NPC1RAB9A
SCHEMBL28855220 0.85 MAPK9 (0.51) EGFRMAPK9MAPK10PLK2PLK1
SCHEMBL2049367 0.85 MAPK9 (0.48) EGFRMEN1KMT2ALMNAMAPK9
SCHEMBL10035798 0.85 MAPK9 (0.51) EGFRMEN1KMT2ALMNAMAPK9
SCHEMBL27708838 0.83 ALDH1A1 (0.43) TSHRMAPK9MAPK10NPC1RAB9A
SCHEMBL27729355 0.83 MAPKAPK2 (0.55) MAPK9MAPK10KDRPTGS2
SCHEMBL27310589 0.83 MAPK9 (0.43) MEN1KMT2AMAPK9MAPK10NPC1
SCHEMBL28354286 0.83 NPC1 (0.45) MEN1KMT2ATSHRACHELMNA
SCHEMBL13309568 0.83 MAPK9 (0.60) MEN1KMT2ALMNAMAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 US disclosed
EP-1660500-A1 SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-05-31 EP disclosed
WO-2005014598-A1 SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 EGFR 4826/4885MEN1 4618/4885KMT2A 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.